Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis

International Immunopharmacology

Volumn 21, Issue 2, 2014, Pages 481-486

  De Andrade, Kenia Rodrigues ^a   De Castro, Gláucio Ricardo Werner ^b   Vicente, Geison ^c   Da Rosa, Julia Salvan ^c   Nader, Marina ^c   Pereira, Ivanio Alves ^a   Fröde, Tânia Silvia ^c  

^a Professor Polydoro Ernani de São Thiago University Hospital   (Brazil)

^b HOSPITAL GOVERNADOR CELSO RAMOS   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Axial spondyloarthritis; Bone alkaline phosphatase; DKK 1; Osteoprotegerin; Pro inflammatory mediators

Indexed keywords

ADENOSINE DEAMINASE; ALKALINE PHOSPHATASE BONE ISOENZYME; DICKKOPF 1 PROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AXIAL SPONDYLOARTHRITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; COLORIMETRY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLITE; OSSIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SPONDYLARTHRITIS; BLOOD; BONE DEVELOPMENT; BONE REMODELING; CASE CONTROL STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

ADULT; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BONE REMODELING; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OSTEOGENESIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903145982     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.05.031     Document Type: Article

References (43)

1. M.C. Hockberg, A.J. Silman, J.S. Smolen, M.E. Weinblatt, and M.H. Weisman Rheumatology 4th ed. 2007 Elsevier Philadelphia 1109 1113
2. R.J.U. Lories, and G. Schett Pathophysiology of new bone formation and ankylosis in spondyloarthritis Rheum Dis Clin North Am 38 2012 555 567
3. J.A. Smith, E. Märker-Hermann, and R.A. Colbert Pathogenesis of ankylosing spondylitis: current concepts Best Pract Res Clin Rheumatol 20 3 2009 571 591 (Pubitemid 44182767)
4. Gran Jt, and J.F. Skomsvoll The outcome of ankylosing spondylitis: a study of 100 patients Br J Rheumatol 36 1997 766 771
5. J. Sieper, H. Appel, J. Braun, and M. Rudwaleit Critical appraisal of assessment of structural damage in ankylosing spondylitis - implications for treatment outcomes Arthritis Rheum 58 3 2008 649 656 (Pubitemid 351364862)
6. J. Braun, M. Bollow, L. Neure, E. Seipelt, F. Seyrekbasan, and H. Herbst et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis Arthritis Rheum 38 1995 499 505
7. R.J. Francois, L. Neure, J. Sieper, and J. Braun Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases Ann Rheum Dis 65 2006 713 720 (Pubitemid 43799168)
8. J.C. Davis Jr., D. Van Der Heijde, J. Braun, M. Dougados, J. Cush, and D.O. Clegg et al. Enbrel ankylosing spondylitis study group: recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis Rheum 48 2003 3230 3236 (Pubitemid 37409337)
9. W. Marhoffer, H. Stracke, I. Masoud, M. Scheja, V. Graef, and W. Bolten et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis Ann Rheum Dis 54 7 1995 556 559
10. G. Schett, L.C. Coates, Z.R. Ash, S. Finzel, and P.G. Conaghan Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future Arthritis Res Ther 13 Suppl. 1 2011 S4 10.1186/1478-6354-13-S1-S4
11. G. Schett Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations Am J Med Sci 341 4 2011 269 271
12. H. Appel, L. Janssen, J. Liting, R. Heydrich, M. Rudwaleit, and J. Sieper Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spodyloarthritis with and without tumor necrosis factor-alpha blocker treatment Arthritis Res Ther 10 2008 R125 10.1186/ar2537
13. T.N. Crotti, M.D. Smith, H. Weedon, M.J. Ahern, D.M. Findlay, and M. Kraan et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis Ann Rheum Dis 61 12 2002 1047 1054 (Pubitemid 35397349)
14. J. Grisar, P.M. Bernecker, M. Aringer, K. Redlich, M. Sedlak, and W. Wolozcszuk et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation J Rheumatol 29 7 2002 1430 1436 (Pubitemid 34755610)
15. H. Franck, T. Meurer, and L.C. Hofbauer Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis J Rheumatol 31 2004 2236 2241 (Pubitemid 39453245)
16. D. Diarra, M. Stolina, K. Polzer, J. Zwerina, M.S. Ominsky, and D. Dwyer et al. Dickkopf-1 is a master regulator of joint remodeling Nat Med 13 2007 156 163
17. C. Yazici, K. Köse, M. Calis, Kuzugüden, and M. Kirnap Protein oxidation status in patients with ankylosing spondylitis Rheumatology 43 2004 1235 1239 (Pubitemid 39359296)
18. M. Karakoc, O. Altindag, H. Keles, N. Soran, and S. Selek Serum oxidative-antioxidative status in patients with ankylosing spondylitis Rheumatol Int 27 2007 1131 1134 (Pubitemid 47373938)
19. L.K. Stamp, I. Khalilova, J.M. Tarr, R. Senthilmohan, R. Turner, and R.C. Haigh et al. Myeloperoxidase and oxidative stress in rheumatoid arthritis Rheumatology 51 2012 1796 1803
20. B. Zamani, R. Jamali, and A. Jamali Serum adenosine deaminase may predict disease activity in rheumatoid arthritis Rheumatol Int 32 7 2012 1967 1975
21. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects http://www.wma.net/en/30publications/10policies/b3/ index.html 2008 [Acessed 6 september 2012]
22. S. Van der Linden, H.A. Valkenburg, and A. Cats Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria Arthritis Rheum 27 1984 361 368 (Pubitemid 14134775)
23. M. Rudwaleit, Van der Heijde, and R. Landewe The development of Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axial spondyloarthritis: validation and final selection Ann Rheum Dis 68 6 2009 777 783
24. L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum Analysis of nitrate, nitrite and [15N] nitrate in biological fluids Anal Biochem 126 1 1982 131 138 (Pubitemid 13203451)
25. T.S. Rao, J.L. Currie, A.L. Shaffer, and P.C. Isakson Comparative evaluation of arachidonic acid (aa)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation Inflammation 17 1993 723 741 (Pubitemid 23359094)
26. G. Giusti, and B. Galanti Adenosine deaminase: colourimetric method. Methods of enzymatic analysis 1984 Verlag Chemie Weinheim 315 323
27. T.R. Jenkinson, P.A. Mallorie, H.C. Whitelock, L.G. Kennedy, S.L. Garrett, and A. Calin Defining spinal mobility in ankylosing spondylitis (the bath as metrology index) J Rheumatol 21 9 1994 1694 1698 (Pubitemid 24285485)
28. A. Calin, S. Garrett, H. Whitelock, L.G. Kennedy, J. O'Hea, and P. Mallori et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index J Rheumatol 21 1994 2281 2285
29. S. Garrett, T. Jenkinson, L.G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index J Rheumatol 21 1994 2286 2291
30. A. Bal, E. Unlu, G. Bahar, E. Aydog, E. Eksioglu, and R. Yorgancioglu Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis Clin Rheumatol 26 2007 211 215 (Pubitemid 46020247)
31. J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, and W. Golder et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 2002 1187 1193 (Pubitemid 34304258)
32. D. Van der Heijde, A. Kivitz, M.H. Schiff, J. Sieper, B.A. Dijkmans, and J. Braun et al. The ATLAS study group efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 54 2006 2136 2146 (Pubitemid 44051069)
33. D. Van der Heijde, R. Landewe, S. Einstein, P. Ory, D. Vosse, and L. Ni et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept Arthritis Rheum 58 5 2008 1324 1333
34. X. Baraliakos, H. Haibel, J. Listing, J. Sieper, and J. Braun Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis Ann Rheum Dis 2013 10.1136/annrheumdis-2012-202698
35. J. Braun, X. Baraliakos, K.G. Hermann, A. Deodhar, D. van der Heijde, and R. Inman et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial Ann Rheum Dis 2013 10.1136/annrheumdis-2012-203075
36. A. Wanders, D. Heijde, R. Landewe, J.M. Behier, A. Calin, and I. Olivieri et al. Non steroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial Arthritis Rheum 52 2005 1756 1765 (Pubitemid 40852884)
37. M. Lotz The role of nitric oxide in articular cartilage damage Rheum Dis Clin North Am 25 2 1999 269 282 (Pubitemid 29267883)
38. K.J. Ho, P.Q. Chen, C.Y. Chang, and F.J. Lu The oxidative metabolism of circulating phagocytes in ankylosing spondylitis: determination by whole blood chemiluminescence Ann Rheum Dis 59 5 2000 338 341
39. N.J. Goodstone, and T.E. Hardingham Tumour necrosis factor alpha stimulates nitric oxide production more potently than interleukin-1beta in porcine articular chondrocytes Rheumatol 41 8 2002 883 891
40. D. Lamarque, J.T. Nhieu, M. Breban, C. Bernardeau, N. Martin-Garcia, and Z. Szepes et al. Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic of ankylosing spondylitis J Rheumatol 30 11 2003 2428 2436 (Pubitemid 37413905)
41. S.R. Kwon, M.J. Lim, S.H. Suh, S.G. Park, Y.S. Hong, and B.Y. Yoon et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy Rheumatol Int 32 2012 2523 2527
42. A. Taylan, I. Sari, B. Akinci, S. Bilge, D. Kozaci, and S. Akar et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis BMC Musculoskelet Disord 13 2012 191 10.1186/1471-2474-13-191
43. D. Daoussis, S.N. Liossis, E.E. Solomou, A. Tsanaktsi, K. Bounia, and M. Karampetsou et al. Evidence that DKK-1 is dysfunctional in ankylosing spondylitis Arthritis Rheum 62 2010 150 158